# Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma

> **NCT04835129** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Medical College of Wisconsin** · enrollment: 28 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Isatuximab (for run-in portion)
- **DRUG:** Isatuximab (for expansion)
- **DRUG:** Pomalidomide
- **DRUG:** Elotuzumab
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT04835129
- **Lead sponsor:** Medical College of Wisconsin
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-01-10
- **Primary completion:** 2027-04-01
- **Final completion:** 2027-06-01
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2026-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04835129

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04835129, "Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT04835129. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*